# LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
Canonical URL: https://biopharmsignal.com/news/LIXT/lixte-biotechnology-files-first-quarter-2026-quarterly-report-on-form-10-q-provides-operational-progress-update
Ticker: LIXT
Company: Lixte Biotechnology Holdings
Source: Lixte Biotechnology Holdings
Published: 2026-05-14 21:18 EST
Original Source URL: https://ir.lixte.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-03 12:30 EST — [LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth](https://biopharmsignal.com/news/LIXT/lixte-biotechnology-announces-16-566-027-registered-direct-offering-priced-at-the-market-under-nasdaq-rules-strengthening-balance-sheet-for-next-phase-of-strategic-growth) — Source: Lixte Biotechnology Holdings
- 2026-06-01 12:50 EST — [LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors](https://biopharmsignal.com/news/LIXT/lixte-biotechnology-announces-strategic-transformation-into-ai-energy-infrastructure-equipment-and-services-stuart-d-porter-founder-of-denham-capital-to-join-board-of-directors) — Source: Lixte Biotechnology Holdings
- 2026-05-14 21:18 EST — [LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update](https://biopharmsignal.com/news/LIXT/lixte-biotechnology-files-first-quarter-2026-quarterly-report-on-form-10-q-provides-operational-progress-update) — Source: Lixte Biotechnology Holdings
- 2026-04-13 12:00 EST — [Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference](https://biopharmsignal.com/news/LIXT/favorable-results-of-ovarian-cancer-study-presented-at-annual-society-of-gynecological-care-conference) — Source: Lixte Biotechnology Holdings
- 2026-03-31 19:45 EST — [LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year](https://biopharmsignal.com/news/LIXT/lixte-biotechnology-files-2025-annual-report-on-form-10k-provides-operational-highlights-of-transformative-year) — Source: Lixte Biotechnology Holdings
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)